Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
21.53B
Market cap21.53B
Price-Earnings ratio
-24.01
Price-Earnings ratio-24.01
Dividend yield
—
Dividend yield—
Average volume
3.30M
Average volume3.30M
High today
$100.31
High today$100.31
Low today
$98.33
Low today$98.33
Open price
$98.82
Open price$98.82
Volume
1.70M
Volume1.70M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

With a market cap of 21.53B, Insmed Incorporated(INSM) trades at $98.56. The stock has a price-to-earnings ratio of -24.01.

On 2026-10-13, Insmed Incorporated(INSM) stock moved within a range of $98.33 to $100.31. With shares now at $98.56, the stock is trading +0.2% above its intraday low and -1.7% below the session's peak.

Trading activity shows a volume of 1.7M, compared to an average daily volume of 3.3M.

Over the past 52 weeks, Insmed Incorporated(INSM) stock has traded between a high of $212.75 and a low of $90.39.

Over the past 52 weeks, Insmed Incorporated(INSM) stock has traded between a high of $212.75 and a low of $90.39.

INSM News

TipRanks 18h
Insmed price target lowered to $207 from $214 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on Insmed (INSM) to $207 from $214 and keeps a Buy rating on the shares after updating estimates ahe...

TipRanks 19h
Insmed downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Insmed (INSM) to Peer Perform from Outperform without a price target The firm says finding a pool of comorbid patients for Brinsupri m...

TipRanks 1d
Insmed: Rising Brinsupri Scripts, Reaffirmed Guidance Support Buy Rating and Unchanged $218 Price Target

Maxwell Skor, an analyst from Morgan Stanley, maintained the Buy rating on Insmed. The associated price target remains the same with $218.00. Maxwell Skor has g...

Analyst ratings

96%

of 25 ratings
Buy
96%
Hold
4%
Sell
0%

More INSM News

Investing.com 2d
InvestingPro’s fair value spotted Insmed’s 47% drop 10 months early By Investing.com - Investing.com

...

InvestingPro’s fair value spotted Insmed’s 47% drop 10 months early By Investing.com - Investing.com
Zacks 7d
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Shares of Insmed (INSM Quick QuoteINSM - Free Report) declined nearly 7% on Monday after the company announced that its chief financial officer (CFO), Sar...

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Simply Wall St 7d
Insmed Reaffirms Outlook As Its Undervalued Narrative Faces A Fresh Test

Advertisement What triggered fresh attention on Insmed stock Insmed (INSM) just paired a planned CFO transition with a reaffirmed 2026 revenue outlook for BRI...

Insmed Reaffirms Outlook As Its Undervalued Narrative Faces A Fresh Test

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.